MCID: ESP024
MIFTS: 62

Esophagitis

Categories: Gastrointestinal diseases, Infectious diseases

Aliases & Classifications for Esophagitis

MalaCards integrated aliases for Esophagitis:

Name: Esophagitis 12 29 55 44 15 73
Acute Esophagitis 12 73

Classifications:



External Ids:

Disease Ontology 12 DOID:11963
ICD10 33 K20 K20.9
ICD9CM 35 530.1 530.10
MeSH 44 D004941
NCIt 50 C9224
SNOMED-CT 68 16761005

Summaries for Esophagitis

MalaCards based summary : Esophagitis, also known as acute esophagitis, is related to peptic esophagitis and esophageal disease, and has symptoms including pain in esophagus (finding) An important gene associated with Esophagitis is CCL26 (C-C Motif Chemokine Ligand 26), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Trimebutine and Rabeprazole have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and bone, and related phenotypes are growth/size/body region and homeostasis/metabolism

Wikipedia : 76 Esophagitis (or oesophagitis) is an inflammation of the esophagus. The prefix esophag/o refers to the... more...

Related Diseases for Esophagitis

Diseases in the Esophagitis family:

Bacterial Esophagitis Viral Esophagitis

Diseases related to Esophagitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1050)
# Related Disease Score Top Affiliating Genes
1 peptic esophagitis 33.8 CXCL8 CYP2C19 HRH2 IL1B
2 esophageal disease 33.1 CCL26 HRH2 PTGS2 TP53 TRPV1
3 esophagitis, eosinophilic, 1 33.1 CCL11 CCL26 DSG1 IL13 IL5 TSLP
4 gastroesophageal reflux 32.2 CCL26 CXCL8 CYP2C19 HRH2 IL1B PTGS2
5 kaposi sarcoma 31.7 CCR3 CXCL8 IL6 TP53
6 helicobacter pylori infection 30.7 CXCL8 CYP2C19 IL1B
7 acquired immunodeficiency syndrome 30.5 IL1B IL6 TP53
8 gastritis 30.4 CXCL8 HRH2 IL1B PTGS2
9 gastric adenocarcinoma 30.4 CXCL8 IL1B PTGS2 TP53
10 duodenal ulcer 30.3 CXCL8 CYP2C19 HRH2 IL1B
11 chagas disease 30.2 CXCL8 IL1B IL6 TGFB1
12 atrophic gastritis 30.2 CXCL8 IL1B TP53
13 viral infectious disease 30.2 CXCL8 IL1B IL6
14 hypereosinophilic syndrome 30.2 CCL11 IL13 IL5
15 pharyngitis 30.1 CXCL8 IL1B PTGS2
16 sleep apnea 30.0 CXCL8 IL1B IL6
17 colitis 30.0 CXCL8 IL1B IL6 PTGS2
18 peptic ulcer disease 30.0 CXCL8 CYP2C19 HRH2 IL1B PTGS2
19 gastric ulcer 30.0 CXCL8 CYP2C19 HRH2 IL1B PTGS2
20 interstitial lung disease 30.0 CXCL8 IL1B IL6 TGFB1
21 acute respiratory distress syndrome 30.0 CXCL8 IL1B IL6
22 eosinophilic gastroenteritis 29.9 CCL11 IL5 TSLP
23 laryngitis 29.9 HRH2 IL1B IL6 TGFB1
24 fatty liver disease 29.8 CXCL8 IL1B IL6
25 meningitis 29.8 CXCL8 IL1B IL6
26 osteomyelitis 29.8 CXCL8 IL1B IL6
27 cytomegalovirus infection 29.8 CXCL8 IL1B IL6
28 peritonitis 29.8 CXCL8 IL1B IL6
29 dyspepsia 29.7 CXCL8 CYP2C19 HRH2 PTGS2 TRPV1
30 lung disease 29.7 CXCL8 IL13 IL1B IL5 IL6 TGFB1
31 pneumonia 29.6 CCL11 CXCL8 IL13 IL1B IL5 IL6
32 gastroenteritis 29.6 CCL11 CXCL8 IL1B IL5 IL6 TSLP
33 active peptic ulcer disease 29.5 HRH2 PTGS2
34 squamous cell carcinoma, head and neck 29.5 CXCL8 PTGS2 TGFB1 TP53
35 paraneoplastic syndromes 29.5 IL1B IL6
36 ureteral obstruction 29.5 PTGS2 TGFB1 TP53
37 pulmonary fibrosis, idiopathic 29.5 CXCL8 IL13 IL1B TGFB1
38 aging 29.5 SOD2 TGFB1 TP53
39 bacterial infectious disease 29.4 CXCL8 IL1B IL6
40 newborn respiratory distress syndrome 29.4 CXCL8 IL1B IL6
41 periodontitis 29.4 CXCL8 IL1B IL6
42 recurrent respiratory papillomatosis 29.4 IL13 PTGS2
43 pneumoconiosis 29.3 CXCL8 IL1B IL6 TGFB1
44 cholangiocarcinoma 29.3 IL6 PTGS2 TGFB1 TP53
45 allergic rhinitis 29.3 CCL11 CXCL8 IL13 IL5
46 bullous pemphigoid 29.3 CCL11 DSG1 IL5
47 interstitial cystitis 29.3 CXCL8 IL6 TRPV1
48 bacterial pneumonia 29.3 CXCL8 IL6 TRPV1
49 arteries, anomalies of 29.3 IL1B IL6 TRPV1
50 arthritis 29.2 CXCL8 IL1B IL6 PTGS2 TGFB1

Comorbidity relations with Esophagitis via Phenotypic Disease Network (PDN): (show top 50) (show all 112)


Active Peptic Ulcer Disease Acute Cystitis
Acute Maxillary Sinusitis Acute Pancreatitis
Alcoholic Gastritis Allergic Rhinitis
Angina Pectoris Anxiety
Aortic Valve Disease 1 Atrophic Gastritis
Basilar Artery Insufficiency Benign Essential Hypertension
Bronchiectasis Bronchitis
Bronchopneumonia Cerebrovascular Disease
Cholecystitis Cholestasis
Chronic Intestinal Vascular Insufficiency Chronic Kidney Failure
Chronic Maxillary Sinusitis Chronic Myocardial Ischemia
Chronic Pulmonary Heart Disease Chronic Rhinitis
Chylomicron Retention Disease Conn's Syndrome
Conversion Disorder Cystitis
Deficiency Anemia Dependent Personality Disorder
Dermatomycosis Diabetic Polyneuropathy
Duodenitis Dyskinesia of Esophagus
Dysthymic Disorder Esophageal Cancer
Esophageal Candidiasis Esophageal Disease
Esophageal Varix First-Degree Atrioventricular Block
Gallbladder Disease Gastrin Secretion Abnormality
Gastritis, Familial Giant Hypertrophic Gastroesophageal Reflux
Generalized Anxiety Disorder Generalized Atherosclerosis
Heart Disease Hepatitis
Hyperlipoproteinemia, Type Iv Hyperlipoproteinemia, Type V

Graphical network of the top 20 diseases related to Esophagitis:



Diseases related to Esophagitis

Symptoms & Phenotypes for Esophagitis

UMLS symptoms related to Esophagitis:


pain in esophagus (finding)

MGI Mouse Phenotypes related to Esophagitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.17 DSG1 IL13 IL1B IL5 IL6 PTGS2
2 homeostasis/metabolism MP:0005376 10.15 CCR3 HRH2 IL13 IL1B IL5 IL6
3 hematopoietic system MP:0005397 10.14 CCL11 CCR3 IL13 IL1B IL5 IL6
4 immune system MP:0005387 10.1 CCL11 CCR3 IL13 IL1B IL5 IL6
5 digestive/alimentary MP:0005381 10.06 HRH2 IL13 IL5 IL6 PTGS2 TGFB1
6 adipose tissue MP:0005375 10.02 DSG1 IL6 PTGS2 SOD2 TGFB1 TP53
7 integument MP:0010771 9.96 DSG1 IL13 IL1B IL6 PTGS2 SOD2
8 liver/biliary system MP:0005370 9.7 IL5 IL6 PTGS2 SOD2 TGFB1 TP53
9 neoplasm MP:0002006 9.56 IL1B IL5 IL6 PTGS2 SOD2 TGFB1
10 respiratory system MP:0005388 9.28 CCL11 CCR3 IL13 IL5 IL6 PTGS2

Drugs & Therapeutics for Esophagitis

Drugs for Esophagitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 317)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trimebutine Approved Phase 4 39133-31-8
2
Rabeprazole Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 117976-89-3 5029
3
Dexlansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 103577-45-3, 138530-94-6 9578005
4
Lansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 103577-45-3 3883
5
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 73590-58-6 4594
6
Dopamine Approved Phase 4,Phase 3,Not Applicable 51-61-6, 62-31-7 681
7
Domperidone Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 57808-66-9 3151
8
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 161796-78-7, 119141-88-7 4594 9579578
9
Fluticasone Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable 90566-53-3 62924
10
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 150399-23-8, 137281-23-3 446556 60843
11
leucovorin Approved Phase 4,Phase 3,Phase 1,Phase 2 58-05-9 6006 143
12
Pantoprazole Approved Phase 4,Phase 3,Phase 2 102625-70-7 4679
13
Budesonide Approved Phase 4,Phase 3,Phase 2,Not Applicable 51333-22-3 63006 5281004
14
Alginic acid Approved, Investigational Phase 4 9005-32-7
15
Ranitidine Approved Phase 4,Phase 3,Phase 1 66357-35-5, 66357-59-3 3001055
16
Iron Approved Phase 4 7439-89-6 23925
17
Deferasirox Approved, Investigational Phase 4 201530-41-8 5493381
18
Verapamil Approved Phase 4 52-53-9 2520
19
Zinc Approved, Investigational Phase 4 7440-66-6
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 59-30-3 6037
21
Serine Approved, Nutraceutical Phase 4 56-45-1 5951
22
Maleic acid Experimental Phase 4,Not Applicable 110-16-7 444266
23 Rebamipide Investigational Phase 4 90098-04-7
24
Polaprezinc Experimental Phase 4 107667-60-7
25 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Parasympatholytics Phase 4
27 Proton Pump Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Antacids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
30 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Dopamine Antagonists Phase 4,Phase 3,Not Applicable
33 Antiemetics Phase 4,Phase 3,Not Applicable
34 Dopamine Agents Phase 4,Phase 3,Not Applicable
35 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Dermatologic Agents Phase 4,Phase 3,Phase 2,Not Applicable
39 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Anti-Allergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Bronchodilator Agents Phase 4,Phase 3,Phase 2,Not Applicable
44 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Protective Agents Phase 4,Phase 2,Phase 1
47 Vitamin B Complex Phase 4,Phase 3,Phase 1,Phase 2
48 Vitamin B9 Phase 4,Phase 3,Phase 1,Phase 2
49 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
50 Folic Acid Antagonists Phase 4,Phase 3,Phase 1,Phase 2

Interventional clinical trials:

(show top 50) (show all 493)
# Name Status NCT ID Phase Drugs
1 Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole Unknown status NCT02986685 Phase 4 Trimebutine Maleate;rabeprazole
2 Treatment Effect Between Dexlansoprazole and Double-dose Lansoprazole in Obesity Patients With Reflux Esophagitis Unknown status NCT02759393 Phase 4 Dexlansoprazole;Lansoprazole
3 Research of Efficient Use of Omeprazole in Combination With Domperidone in Gastroesophageal Reflux Disease of Mild to Moderate Severity Unknown status NCT02140073 Phase 4 omeprazole+domperidone SR;omeprazole
4 Transoral Incisionless Fundoplication (TIF) Versus Sham for Treatment of Gastroesophageal Reflux Disease (GERD) Unknown status NCT01110811 Phase 4
5 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Wu-Chu-Yu Tang on Gastroesophageal Reflux Disease (GERD) Unknown status NCT01822106 Phase 4
6 The Randomized Controlled Clinical Trial of Kushen Injection Unknown status NCT02346318 Phase 4 Compound Kushen Injection
7 An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis Completed NCT01008696 Phase 4 Rabeprazole;Lansoprazole
8 Intravenous (IV) Pantoprazole in Erosive Esophagitis Completed NCT00133770 Phase 4 pantoprazole
9 Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis Completed NCT02371941 Phase 4 oral cromolyn sodium;Placebo
10 Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study Completed NCT00693225 Phase 4 Omeprazole/sodium bicarbonate
11 Rate of Complete Symptom Relief, Prevention of Symptom Relapse: Grades A and B Esophagitis of Esomeprazole Therapy Completed NCT01874535 Phase 4 Esomeprazole 40 mg
12 A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Erosive Esophagitis Completed NCT00641602 Phase 4 Esomeprazole;Lansoprazole
13 Dietetic Versus Topical Steroids for Pediatric Eosinophilic Esophagitis Completed NCT01846962 Phase 4 Budesonide;Fluticasone;Oral Viscous Budesonide (OVB)
14 Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory Evaluation Completed NCT03116841 Phase 4 Vonoprazan
15 NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis Completed NCT00206180 Phase 4 esomeprazole magnesium (oral medication)
16 The Study to Evaluate Efficacy and Safety of Newrabell® Tab.(Rabeprazole Sodium) 10mg b.i.d in Refractory GERD Completed NCT01860482 Phase 4 Newrabell® Tablet 10mg
17 A Study to Evaluate REbamiPide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis Completed NCT02755753 Phase 4 Lansoprazole;Rebamipide;Rebamipide-placebo
18 Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been Healed Completed NCT00644735 Phase 4 Esomeprazole;Lansoprazole
19 Esomeprazole for Treatment of GERD in Pediatric Patients Completed NCT00228527 Phase 4 Esomeprazole (Nexium)
20 An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00242736 Phase 4 Esomeprazole
21 Role of Pepsin Assay in Wheezy Infants Completed NCT02685436 Phase 4 Omeprazole and domperidone
22 To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole Completed NCT01397084 Phase 4 esomeprazole 20 mg
23 Dexlansoprazole in Asian Participants With Gastroesophageal Reflux Disease Completed NCT02351960 Phase 4 Dexlansoprazole
24 The Prospective Study on the Effect of Ilaprazole in Non-erosive Reflux Disease Patients; Focused on Histologic Findings and Inflammatory Biomarker Completed NCT02666976 Phase 4 Ilaprazole
25 An Open-Label Trial of Dexlansoprazole 60mg for the Relief of Heartburn During the Fasting Month of Ramadan Completed NCT03079050 Phase 4 Dexlansoprazole 60 MG
26 Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients Completed NCT00574925 Phase 4 Esomeprazole
27 A Study of Rabeprazole and Pantoprazole on Stomach Acid and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease (GERD) and a History of Nighttime Heartburn Completed NCT00237367 Phase 4 rabeprazole and pantoprazole
28 Do Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux Predict Response to Treatment? Completed NCT00444145 Phase 4 Prevacid
29 Nissen and Gastroplasty in Gastroesophageal Reflux Disease (GERD) Completed NCT00872755 Phase 4
30 Chemotherapy for Patients With Non-Small Cell Lung Cancer Completed NCT00380718 Phase 4 pemetrexed
31 EoE RCT Fluticasone and Omeprazole vs Fluticasone Alone Recruiting NCT03781596 Phase 4 Fluticasone;Omeprazole;Placebo oral capsule
32 Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis Recruiting NCT03372083 Phase 4 Deferasirox
33 Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation Recruiting NCT02067182 Phase 4 Dabigatran
34 Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety Active, not recruiting NCT02679508 Phase 4 Vonoprazan;Lansoprazole
35 Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis Active, not recruiting NCT02019758 Phase 4 Oral Viscous Budesonide;Fluticasone MDI;Placebo slurry;Placebo inhaler
36 Efficacy of Zinc L-carnosine in Maintaining Remission of Gastroesophageal Reflux Disease Not yet recruiting NCT03467438 Phase 4 Zinc-l-carnosine
37 The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors Terminated NCT01404832 Phase 4 Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms
38 Lansoprazole Preventing Gastroduodenal Stress Ulcerations Terminated NCT00220909 Phase 4 Lansoprazole
39 The Clinical Significance of Acid Rebound in Functional Dyspepsia Terminated NCT01373970 Phase 4 Placebo;Pantoprazole + Placebo
40 Dexilant Treatment in Gastrointestinal Reflux Disease (GERD Related Non Cardiac Chest Pain Withdrawn NCT01637571 Phase 4 Dexilant;Dexilant Placebo
41 Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone Unknown status NCT01702701 Phase 3 Montelukast;Fluticasone
42 The Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancer(NSCLC) Unknown status NCT02076477 Phase 3 Docetaxel;pemetrexed;Cisplatin
43 Laparoscopic Repair of Giant Hiatal Hernias With Nitinol-framed Lightweight Polytetrafluoroethylene Mesh Unknown status NCT01780285 Phase 3
44 Laparoscopic Lightweight Mesh Repair of Large Hiatal Hernias Unknown status NCT01408108 Phase 3
45 Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis Completed NCT02456935 Phase 3 CJ-12420 100 mg QD;Esomeprazole 40 mg QD
46 Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis Completed NCT03006874 Phase 3 CJ-12420 100mg QD;Esomeprazole 40mg;CJ-12420 50mg QD
47 Reflux Esophagitis Phase III Study (Maintenance Treatment) Completed NCT00634114 Phase 3 Esomeprazole;Esomeprazole;Omeprazole
48 Efficacy and Safety of Vonoprazan Compared to Lansoprazole in the Maintenance Treatment of Erosive Esophagitis Completed NCT02388737 Phase 3 Vonoprazan;Lansoprazole;Vonoprazan Placebo;Lansoprazole Placebo
49 Reflux Esophagitis Phase III Study (Initial Treatment) Completed NCT00633932 Phase 3 Esomeprazole;Esomeprazole;Omeprazole
50 Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Erosive Esophagitis Completed NCT01452698 Phase 3 TAK-438;Placebo;Lansoprazole;Placebo

Search NIH Clinical Center for Esophagitis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: esophagitis

Genetic Tests for Esophagitis

Genetic tests related to Esophagitis:

# Genetic test Affiliating Genes
1 Esophagitis 29

Anatomical Context for Esophagitis

MalaCards organs/tissues related to Esophagitis:

41
Lung, Testes, Bone, T Cells, Liver, Kidney, Brain

Publications for Esophagitis

Articles related to Esophagitis:

(show top 50) (show all 2844)
# Title Authors Year
1
Eosinophilic Esophagitis. ( 30466674 )
2019
2
Unique Clinical Features of Los Angeles Grade D Esophagitis Suggest That Factors Other Than Gastroesophageal Reflux Contribute to its Pathogenesis. ( 28644313 )
2019
3
Eosinophilic Esophagitis Is a Late Manifestation of the Allergic March. ( 29954692 )
2018
4
Clinical Translation of Tethered Confocal Microscopy Capsule for Unsedated Diagnosis of Eosinophilic Esophagitis. ( 29422678 )
2018
5
Blind esophageal brushing offers a safe and accurate method to monitor inflammation in children and young adults with eosinophilic esophagitis. ( 29905784 )
2018
6
Heterogeneity in Clinical, Endoscopic, and Histologic Outcome Measures and Placebo Response Rates in Clinical Trials of Eosinophilic Esophagitis: A Systematic Review. ( 29908360 )
2018
7
Airborne and food sensitization patterns in children and adults with eosinophilic esophagitis. ( 29381255 )
2018
8
Epithelial origin of eosinophilic esophagitis. ( 29980278 )
2018
9
Esophagitis dissecans superficialis due to severe nonsteroidal anti-inflammatory drugs toxicity. ( 29907463 )
2018
10
Association of mast cells with clinical, endoscopic, and histologic findings in adults with eosinophilic esophagitis. ( 29935026 )
2018
11
Changing Concept of the Prevalence of Eosinophilic Esophagitis: Visible and Hidden Patients. ( 29969848 )
2018
12
Possible Risk Factors for Candida Esophagitis in Immunocompetent Individuals. ( 29915629 )
2018
13
Comment on: Clinical Characteristics of Severe Erosive Esophagitis among Patients with Erosive Esophagitis: A Case-control Study. ( 29434125 )
2018
14
Understanding fibrosis in eosinophilic esophagitis: Are we there yet? ( 29377264 )
2018
15
Eosinophilic Esophagitis Through the Flexible Endoscope and the Lens of a Photographer in the Amazon. ( 29427131 )
2018
16
Practice Differences in the Diagnosis and Management of Eosinophilic Esophagitis among Adult and Pediatric Gastroenterologists in Israel. ( 29394215 )
2018
17
Is eosinophilic esophagitis a member of the atopic march? ( 29413330 )
2018
18
Is eosinophilic esophagitis an equivalent of pollen allergic asthma? Analysis of biopsies and therapy guided by component resolved diagnosis. ( 29338961 )
2018
19
Eosinophilic esophagitis and symptoms possibly related to eosinophilic esophagitis in oral immunotherapy. ( 29397272 )
2018
20
Incidence and Prevalence of Pediatric Eosinophilic Esophagitis in Utah Based on a 5-Year Population-Based Study. ( 29935329 )
2018
21
Esophagitis associated with multimodality management of pediatric Ewing sarcoma of thorax. ( 29431250 )
2018
22
Genetic variants at the 16p13 locus confer risk for eosinophilic esophagitis. ( 29904099 )
2018
23
Association between Minimal Change Esophagitis and Gastric Dysmotility: A Single-Center Electrogastrography and Endoscopy Study in Children. ( 29383301 )
2018
24
Eosinophilic Esophagitis: Treatment With Different Doses of Omeprazole in Children Under 16 Years. ( 29939138 )
2018
25
Allergic components of eosinophilic esophagitis. ( 29980277 )
2018
26
Rising incidence and prevalence of adult eosinophilic esophagitis in midwestern Spain (2007-2016). ( 29435311 )
2018
27
Quail egg homogenate alleviates food allergy induced eosinophilic esophagitis like disease through modulating PAR-2 transduction pathway in peanut sensitized mice. ( 29348584 )
2018
28
Trend, clinical presentations and diagnosis of eosinophilic esophagitis in Saudi children. ( 29968888 )
2018
29
The Author's Reply: Comment on: Clinical Characteristics of Severe Erosive Esophagitis among Patients with Erosive Esophagitis: A Case-control Study. ( 29434142 )
2018
30
Efficacy of vonoprazan for 24-week maintenance therapy of patients with healed reflux esophagitis refractory to proton pump inhibitors. ( 29435273 )
2018
31
Combined and Alternating Topical Steroids and Food Elimination Diet for the Treatment of Eosinophilic Esophagitis. ( 29380175 )
2018
32
Integrin I+M activation and upregulation on esophageal eosinophils and periostin-mediated eosinophil survival in eosinophilic esophagitis. ( 29424023 )
2018
33
Rationale and design of the VISION study: a randomized, open-label study to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive esophagitis. ( 29416369 )
2018
34
Safety and Efficacy of Budesonide Oral Suspension Maintenance Therapy in Patients With Eosinophilic Esophagitis. ( 29902649 )
2018
35
A case of Jackhammer esophagus caused by eosinophilic esophagitis in which per-oral endoscopic myotomy resulted in symptom improvement. ( 29790076 )
2018
36
The Rise and Rise of Eosinophilic Gut Diseases Including Eosinophilic Esophagitis Is Probably Not Explained by the Disappearance of Helicobacter pylori, so Who or What's to Blame? ( 29910462 )
2018
37
Eosinophilic Gastrointestinal Diseases (EGIDs) beyond Eosinophilic Esophagitis (EoE). ( 29940308 )
2018
38
Efficacy of Atopy Patch Testing in Directed Dietary Therapy of Eosinophilic Esophagitis: A Pilot Study. ( 29349695 )
2018
39
Eosinophilic esophagitis and esophageal atresia: coincidence or causality? ( 29333824 )
2018
40
Determinant factors of quality of life in adult patients with eosinophilic esophagitis. ( 29435312 )
2018
41
Obtaining adequate lamina propria for subepithelial fibrosis evaluation in pediatric eosinophilic esophagitis. ( 29309779 )
2018
42
Eosinophilic Esophageal Myositis (EoEM) Causes Jackhammer Esophagus, Rarely Posing a Problem in the Differential Diagnosis of Eosinophilic Esophagitis. ( 29895983 )
2018
43
Maintenance Treatment of Eosinophilic Esophagitis With Swallowed Topical Steroids Alters Disease Course Over A 5-Year Follow-Up Period in Adult Patients. ( 29902648 )
2018
44
Mucosal inflammation in Candida esophagitis has distinctive features that may be helpful diagnostically. ( 29921901 )
2018
45
Mucosal Impedance: a New Approach to Diagnosing Gastroesophageal Reflux Disease and Eosinophilic Esophagitis. ( 29886566 )
2018
46
Prolonged Time to Diagnosis of Eosinophilic Esophagitis Despite Increasing Knowledge of the Disease. ( 29374615 )
2018
47
Can Eosinophilic Esophagitis Cause Achalasia and Other Esophageal Motility Disorders? ( 30315308 )
2018
48
Retention Esophagitis as a Significant Clinical Predictor of Progression to Esophageal Cancer in Achalasia. ( 29506341 )
2018
49
Retention Esophagitis in Patients with Achalasia Requires Cancer Surveillance. ( 29558793 )
2018
50
Esophagitis dissecans superficialis as the first manifestation of rectal adenocarcinoma. ( 30543198 )
2018

Variations for Esophagitis

Expression for Esophagitis

Search GEO for disease gene expression data for Esophagitis.

Pathways for Esophagitis

Pathways related to Esophagitis according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.02 CCL11 CXCL8 DSG1 IL13 IL1B IL5
2
Show member pathways
13.85 CCL11 CCL26 CCR3 CXCL8 IL13 IL1B
3
Show member pathways
13.56 CCL11 CCL26 CCR3 CXCL8 IL13 IL1B
4
Show member pathways
13.55 CCL11 CCL26 CXCL8 IL13 IL1B IL5
5
Show member pathways
13.4 CCL11 CCL26 CCR3 CXCL8 IL13 IL1B
6
Show member pathways
13.37 CCL11 CXCL8 IL13 IL1B IL5 IL6
7
Show member pathways
13.29 CCL11 CCL26 CCR3 CXCL8 IL13 IL1B
8
Show member pathways
13.07 CCR3 CXCL8 IL1B IL6 PTGS2 TGFB1
9
Show member pathways
12.89 CCL11 CXCL8 IL13 IL1B IL5 IL6
10 12.85 CXCL8 IL13 IL5 IL6 PTGS2 TGFB1
11
Show member pathways
12.79 CXCL8 IL13 IL1B IL6 TP53
12
Show member pathways
12.61 IL13 IL1B IL5 IL6 TGFB1
13
Show member pathways
12.44 IL13 IL1B IL5 TP53
14
Show member pathways
12.42 IL1B IL5 IL6 TGFB1
15
Show member pathways
12.39 IL13 IL5 IL6 TSLP
16
Show member pathways
12.36 IL1B IL6 PTGS2 SOD2 TP53
17
Show member pathways
12.35 CXCL8 IL1B IL6 PTGS2 TP53
18
Show member pathways
12.34 CCL11 CCL26 CCR3 CXCL8
19
Show member pathways
12.33 CCL11 CXCL8 IL13 IL1B IL5 IL6
20
Show member pathways
12.29 CXCL8 IL13 IL1B IL5 IL6 TGFB1
21
Show member pathways
12.24 CXCL8 IL1B IL6 PTGS2
22
Show member pathways
12.22 CCL11 CCL26 CCR3 CXCL8 IL1B
23
Show member pathways
12.2 CCL11 CXCL8 IL1B IL6
24 12.2 IL6 PTGS2 TGFB1 TP53
25 12.19 CXCL8 IL13 IL1B IL6
26 12.18 CXCL8 IL6 TGFB1 TP53
27
Show member pathways
12.06 IL13 IL1B IL5 TP53
28
Show member pathways
12.05 CCL11 CCL26 CXCL8 IL13 IL1B IL5
29
Show member pathways
12.03 CCL11 CCL26 CCR3 CXCL8
30 12.03 CXCL8 IL1B IL6 PTGS2 TGFB1 TP53
31 11.99 CXCL8 IL1B IL6 TGFB1 TP53
32 11.97 CCR3 IL5 IL6
33 11.97 SOD2 TGFB1 TP53
34 11.95 IL1B IL6 PTGS2
35 11.95 CXCL8 IL1B IL6 TGFB1
36 11.93 CXCL8 IL1B IL6 TGFB1
37 11.9 CXCL8 IL1B IL6 TGFB1
38 11.89 IL1B IL5 IL6
39 11.88 CXCL8 IL1B PTGS2
40
Show member pathways
11.86 CXCL8 IL6 TGFB1
41 11.86 CXCL8 IL13 IL5 IL6 TP53
42 11.83 CXCL8 IL1B IL6
43 11.83 IL13 IL1B IL5 TSLP
44
Show member pathways
11.77 CXCL8 IL5 PTGS2
45 11.76 CXCL8 IL1B IL6
46 11.75 IL1B IL6 TGFB1
47
Show member pathways
11.72 CXCL8 IL1B IL6 PTGS2
48 11.67 CCL11 CCL26 IL5
49 11.62 CXCL8 IL6 PTGS2 TGFB1 TP53
50 11.61 CXCL8 IL1B IL6

GO Terms for Esophagitis

Cellular components related to Esophagitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 CCL11 CCL26 CXCL8 IL13 IL1B IL5
2 extracellular space GO:0005615 9.28 CCL11 CCL26 CXCL8 IL13 IL1B IL5

Biological processes related to Esophagitis according to GeneCards Suite gene sharing:

(show all 42)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.97 IL6 PTGS2 TGFB1 TP53 TRPV1
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.96 CCL11 CCL26 IL1B TGFB1
3 immune response GO:0006955 9.91 CCL11 CCL26 CCR3 CXCL8 HRH2 IL13
4 chemotaxis GO:0006935 9.9 CCL11 CCL26 CCR3 CXCL8
5 positive regulation of cell migration GO:0030335 9.89 CCL11 CCL26 IL1B SOD2 TGFB1
6 positive regulation of angiogenesis GO:0045766 9.87 CCL11 CCR3 CXCL8 IL1B
7 negative regulation of cell proliferation GO:0008285 9.87 CXCL8 IL1B IL6 PTGS2 SOD2 TGFB1
8 positive regulation of DNA-binding transcription factor activity GO:0051091 9.86 IL1B IL5 IL6
9 response to estradiol GO:0032355 9.86 IL1B PTGS2 TGFB1
10 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.84 IL6 PTGS2 TGFB1
11 cellular response to interleukin-1 GO:0071347 9.84 CCL11 CCL26 CXCL8
12 cellular response to tumor necrosis factor GO:0071356 9.84 CCL11 CCL26 CXCL8 TRPV1
13 memory GO:0007613 9.83 HRH2 IL1B PTGS2
14 protein homotetramerization GO:0051289 9.83 SOD2 TP53 TRPV1
15 positive regulation of endothelial cell proliferation GO:0001938 9.82 CCL11 CCL26 CCR3
16 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.81 IL13 IL6 TSLP
17 response to glucocorticoid GO:0051384 9.81 IL1B IL6 PTGS2
18 regulation of signaling receptor activity GO:0010469 9.81 CCL11 CCL26 CXCL8 IL13 IL1B IL5
19 positive regulation of interleukin-6 production GO:0032755 9.8 IL1B IL6 TSLP
20 positive regulation of smooth muscle cell proliferation GO:0048661 9.8 IL13 IL6 PTGS2
21 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.78 IL5 IL6 TGFB1 TP53
22 monocyte chemotaxis GO:0002548 9.77 CCL11 CCL26 IL6
23 positive regulation of nitric oxide biosynthetic process GO:0045429 9.76 IL1B PTGS2 TRPV1
24 neutrophil chemotaxis GO:0030593 9.73 CCL11 CCL26 CXCL8 IL1B
25 response to radiation GO:0009314 9.72 CCL11 PTGS2 TGFB1
26 cellular response to mechanical stimulus GO:0071260 9.71 IL13 IL1B PTGS2 TGFB1
27 positive regulation of glial cell proliferation GO:0060252 9.69 IL1B IL6
28 positive regulation of vascular endothelial growth factor production GO:0010575 9.69 IL1B PTGS2 TGFB1
29 positive regulation of chemotaxis GO:0050921 9.68 CCL26 TGFB1
30 ovulation GO:0030728 9.67 IL1B PTGS2
31 positive regulation of immunoglobulin secretion GO:0051024 9.67 IL5 IL6
32 chemokine-mediated signaling pathway GO:0070098 9.67 CCL11 CCL26 CCR3 CXCL8
33 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.65 TGFB1 TP53
34 response to vitamin D GO:0033280 9.63 IL1B PTGS2 TGFB1
35 positive regulation of neuroinflammatory response GO:0150078 9.62 IL1B IL6
36 positive regulation of fever generation GO:0031622 9.61 IL1B PTGS2
37 cytokine-mediated signaling pathway GO:0019221 9.61 CCL11 CXCL8 IL13 IL1B IL5 IL6
38 fever generation GO:0001660 9.56 IL1B TRPV1
39 inflammatory response GO:0006954 9.36 CCL11 CCL26 CCR3 CXCL8 IL13 IL1B
40 positive regulation of transcription, DNA-templated GO:0045893 10.08 IL1B IL5 IL6 TGFB1 TP53
41 positive regulation of gene expression GO:0010628 10.01 IL13 IL1B IL6 TGFB1 TP53
42 positive regulation of cell proliferation GO:0008284 10 IL1B IL5 IL6 PTGS2 TGFB1 TSLP

Molecular functions related to Esophagitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine activity GO:0008009 9.33 CCL11 CCL26 CXCL8
2 cytokine activity GO:0005125 9.28 CCL11 CCL26 CXCL8 IL13 IL1B IL5
3 CCR3 chemokine receptor binding GO:0031728 8.96 CCL11 CCL26

Sources for Esophagitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....